QURE — uniQure N.V. Stock Price, Chart & AI Report

Negative Mar 1, 2026 • 22:45 UTC GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE)

A securities fraud class action lawsuit has been filed against uniQure N.V. (NASDAQ: QURE) for allegedly making material misstatements about its Huntington's disease gene therapy drug AMT-130 and the FDA approval timeline. The lawsuit covers investors who purchased shares between September 24 and October 31, 2025. On November 3, 2025, uniQure revealed the FDA no longer agrees that Phase I/II study data may be adequate for a BLA submission, causing the stock to plummet 49% from $67.69 to $34.29 per share.

QURE securities fraud class action lawsuit gene therapy Huntington's disease FDA approval BLA submission stock price decline

Sentiment note

The company is the subject of a securities fraud lawsuit alleging material misstatements about its lead drug candidate AMT-130 and FDA approval prospects. The stock experienced a severe 49% price decline following disclosure that the FDA no longer agrees the trial data is adequate for BLA submission, indicating significant setbacks in the company's clinical development and regulatory timeline.

Negative Mar 1, 2026 • 17:00 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, NATIONAL TRIAL LAWYERS, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE

Rosen Law Firm is notifying investors who purchased uniQure N.V. ordinary shares between September 24, 2025 and October 31, 2025 of an April 13, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that uniQure misrepresented and failed to disclose that the design of its Pivotal Study for its Huntington's Disease drug candidate was not fully FDA-approved, and that the company downplayed the likelihood of delays to its Biologics License Application timeline.

QURE securities class action lead plaintiff deadline FDA approval Biologics License Application Huntington's Disease investor compensation misrepresentation

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations regarding FDA approval status of its Pivotal Study and downplaying of BLA timeline delays. These allegations suggest management failed to disclose material risks to investors, resulting in investor losses.

Negative Feb 27, 2026 • 00:37 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A LEADING NATIONAL FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE

Rosen Law Firm is encouraging investors who purchased uniQure N.V. (NASDAQ: QURE) shares between September 24, 2025 and October 31, 2025 to join a securities class action lawsuit. The lawsuit alleges that uniQure misrepresented and failed to disclose that the design of its Pivotal Study for its Huntington's Disease drug candidate was not fully FDA-approved, and that the company downplayed the likelihood of delays to its Biologics License Application timeline. The lead plaintiff deadline is April 13, 2026.

QURE securities class action FDA approval Biologics License Application Huntington's Disease misrepresentation investor lawsuit

Sentiment note

The company is the subject of a securities class action lawsuit alleging material misrepresentations and omissions regarding FDA approval status of its Pivotal Study and BLA timeline delays. These allegations suggest potential regulatory setbacks and investor losses, which are negative indicators for the company's credibility and stock performance.

Negative Feb 26, 2026 • 03:03 UTC GlobeNewswire Inc. • Claimsfiler

uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

uniQure N.V. faces a securities class action lawsuit for failing to disclose material information about its drug candidate AMT-130. The company previously represented high likelihood of FDA accelerated approval, but on November 3, 2025, disclosed the FDA no longer agrees the Phase I/II data is adequate for a BLA submission. The stock plummeted 49% from $67.69 to $34.29 on the news. Investors with losses exceeding $100,000 have until April 13, 2026 to file lead plaintiff applications.

QURE securities class action FDA approval material information disclosure stock price decline lead plaintiff deadline AMT-130 BLA submission

Sentiment note

Company faces securities litigation for allegedly failing to disclose material information about FDA approval prospects for its lead drug candidate. Stock experienced a severe 49% price decline following disclosure of FDA's rejection of trial data adequacy, indicating significant investor losses and loss of confidence in the company's drug development program.

Negative Feb 25, 2026 • 23:37 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

UNIQURE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm

A class action lawsuit has been filed against uniQure N.V. for allegedly making materially false and misleading statements during September 24 - October 31, 2025. The complaint alleges the company misrepresented FDA approval of its Pivotal Study design and downplayed the likelihood of delays in its BLA submission timeline. Investors who suffered losses can contact the law firm by April 13, 2026 to be appointed as lead plaintiff.

QURE class action lawsuit securities fraud misleading statements Pivotal Study BLA submission FDA approval investor losses

Sentiment note

The company is the subject of a class action lawsuit alleging material misrepresentations and omissions regarding its Pivotal Study FDA approval status and BLA timeline delays, indicating serious regulatory and operational concerns that resulted in investor losses.

Negative Feb 25, 2026 • 02:55 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC has filed securities fraud class action lawsuits against uniQure N.V., Corcept Therapeutics, and BellRing Brands for allegedly failing to disclose material information to investors. uniQure's stock declined 49% after the FDA rejected data supporting its drug candidate AMT-130's accelerated approval. Similar FDA approval issues and inventory problems caused significant stock declines at the other companies. Investors have until April 13, 2026 to file lead plaintiff applications.

QURE BRBR CORT securities fraud class action lawsuit FDA approval stock decline material information disclosure

Sentiment note

Company faces securities fraud allegations for misrepresenting FDA approval likelihood for drug candidate AMT-130. Stock declined 49% after FDA rejected supporting data, causing substantial investor losses.

Negative Feb 25, 2026 • 02:48 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC announced multiple securities fraud class action lawsuits against pharmaceutical and consumer companies. Corcept Therapeutics faces allegations of failing to disclose material information about its relacorilant drug candidate, which received a Complete Response Letter from the FDA instead of approval, causing a 50.4% stock decline. Similar lawsuits were filed against uniQure N.V. for FDA approval delays (49% decline) and BellRing Brands for inventory issues (52% decline). Investors have until April 21, 2026 to file lead plaintiff applications.

CORT QURE BRBR securities fraud class action lawsuit FDA approval stock decline material information disclosure

Sentiment note

Company involved in securities fraud class action related to FDA approval delays, resulting in a 49% stock decline.

Negative Feb 25, 2026 • 02:47 UTC GlobeNewswire Inc. • Kahn Swick & Foti, Llc

BellRing Brands, Inc. Securities Fraud Class Action Result of Inventory Issues and 52% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Kahn Swick & Foti, LLC has filed securities fraud class action lawsuits against BellRing Brands, uniQure N.V., and Corcept Therapeutics for allegedly failing to disclose material information. BellRing's stock declined 52% following inventory and retailer supply issues, uniQure's stock fell 49% due to FDA approval delays, and Corcept's stock dropped 50% related to FDA approval issues. Investors have until March 23, 2026 to file lead plaintiff applications.

QURE CORT BRBR securities fraud class action lawsuit stock decline material information disclosure FDA approval

Sentiment note

Stock declined 49% following FDA approval delays. Securities fraud class action filed for alleged failure to disclose material information related to regulatory approval issues.

Negative Feb 23, 2026 • 17:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against uniQure N.V. alleging that company defendants made materially false and misleading statements regarding FDA approval of their Pivotal Study design and the likelihood of delays to their BLA timeline. The lawsuit covers investors who purchased uniQure securities between September 24, 2025 and October 31, 2025, with a lead plaintiff deadline of April 13, 2026.

QURE class action lawsuit securities fraud uniQure N.V. FDA approval Pivotal Study BLA submission investor harm

Sentiment note

The company is the subject of a securities fraud class action lawsuit alleging material misrepresentations and omissions regarding FDA approval of study design and BLA timeline delays, which directly harms investor interests and indicates serious corporate governance and disclosure failures.

Negative Feb 21, 2026 • 00:04 UTC GlobeNewswire Inc. • Rosen Law Firm

ROSEN, NATIONAL TRIAL LAWYERS, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE

Rosen Law Firm is soliciting investors who purchased shares of uniQure N.V., Vistagen Therapeutics, Inc., and Lufax Holding Ltd during specified periods to join securities class action lawsuits. The uniQure lawsuit alleges the company misrepresented FDA approval of its Pivotal Study design and downplayed delays to its Biologics License Application timeline. The lead plaintiff deadline for uniQure is April 13, 2026.

QURE VTGN LU securities class action FDA approval Biologics License Application Huntington's Disease investor losses

Sentiment note

The company is accused of misrepresenting FDA approval status of its Pivotal Study and failing to disclose likelihood of BLA submission delays, resulting in investor damages when true details emerged.

Negative Feb 20, 2026 • 19:47 UTC GlobeNewswire Inc. • The Schall Law Firm

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased uniQure N.V. (NASDAQ: QURE) securities between September 24, 2025, and October 31, 2025, for a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding FDA approval for its Pivotal Study and misrepresented the timeline for its BLA submission, resulting in investor losses.

QURE securities fraud class action lawsuit FDA approval BLA timeline investor losses Securities Exchange Act

Sentiment note

The company is the subject of a securities fraud lawsuit alleging false and misleading statements about FDA approval and BLA timeline, which caused investor losses. This represents significant legal and reputational risk.

Negative Feb 20, 2026 • 07:09 UTC Benzinga • Prnewswire

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is seeking investors who purchased uniQure N.V. (NASDAQ: QURE) securities between September 24, 2025, and October 31, 2025, to join a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding FDA approval for its Pivotal Study and misrepresented the likelihood of delays to its BLA timeline. Investors who suffered losses are encouraged to contact the firm before April 13, 2026.

QURE securities fraud class action lawsuit FDA approval BLA timeline shareholder rights misleading statements

Sentiment note

The company is facing a securities fraud class action lawsuit for making false and misleading statements about FDA approval prospects and BLA timeline delays, resulting in investor losses and reputational damage.